Key trials of BiTEs in SCLC
| Agent | Tumor target/T cell target | Trial identifier | Phase | ORR | OS | PFS | Grade 3 or > TRAEs |
|---|---|---|---|---|---|---|---|
| Tarlatamab | DLL3/CD3 | DeLLphi-300 (NCT03319940) | I | 23.4% (95% CI: 15.7–32.5) | 13.2 months (95% CI: 10.5–not reached) | 3.7 months (95% CI: 2.1–5.4) | |
| Tarlatamab | DLL3/CD3 | DeLLphi-301 (NCT05060016) | II | 40% (97.5% CI: 29–52) 10 mg, 32% (97.5% CI: 21–44) 100 mg | 4.9 months (95% CI: 2.9–6.7) 10 mg, 3.9 months (95% CI: 2.6–4.4) 100 mg | 26% 10 mg, 33% 100 mg |
BiTEs: bispecific T-cell engagers; SCLC: small cell lung cancer; DLL3: delta-like ligand 3; CI: confidence interval; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; TRAEs: treatment-related adverse events